Articles tagged with Myeloid Cells
Researchers at Nagoya University discovered that complement C3 protein acts inside tumors to prevent immunosuppressive cells, improving cancer immunotherapy effectiveness. Higher levels of C3 in tumor tissue were associated with better treatment outcomes and survival rates in patients.
A study published in Cancer Research identified an immune pathway that promotes the progression of oral precancerous lesions into head and neck squamous cell carcinoma. The researchers found that targeting a key inflammation signal known as interleukin-1 alpha (IL-1α) could help restore immune surveillance and prevent high-risk lesions...
Researchers discovered that the epidermal growth factor receptor (EGFR) influences certain immune cells in the tumour microenvironment, affecting how the body defends against the tumour. Silencing EGFR in myeloid cells led to reduced production of factors inhibiting T cells, allowing them to attack cancer cells more effectively.
Researchers from Chiba University found that antibody therapeutics with stronger Fcγ receptor binding are more likely to be recognized as foreign and associated with higher anaphylaxis risk. High affinities for Fcγ receptors critical determinants of anaphylaxis, study suggests.
Researchers found that eosinophils suppress chordoma growth and induce cell death in tumor cells, suggesting them as a novel immunotherapeutic target. The study's findings provide new insight into the immune mechanisms underlying chordoma progression.
Researchers found that interferon-gamma signaling in myeloid cells corresponds with resistance to immunotherapy in advanced renal cell carcinoma. This study could help identify biomarkers for predicting response to immunotherapy and inform the development of new therapies.
ACTM-838, a novel bacterial immunotherapy, enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity. The therapy shows durable anti-tumor efficacy and synergizes with anti-PD1 drugs, improving outcomes in treatment-resistant tumor models.
Researchers found that telomerase inactivation in immune cells or connective tissue cells slows tumor growth, but creates conditions for aggressiveness. In contrast, endothelial cell preservation suppresses metastasis.
A study reveals that metal-organic frameworks (MOFs) can be toxic to mice, causing disruptions in blood cell formation and immune balance. The researchers found that the MOFs suppressed production of certain cells but also triggered a rebound effect, leading to increased inflammation.
A study from The University of Osaka found that specific white blood cells and an inflammation protein can predict relapse of autoimmune blood vessel disease. Researchers analyzed neutrophils in patients' blood to identify a subpopulation involved in disease progression.
Researchers found that blood cells carrying age-related mutations can infiltrate tumours, leading to worse cancer outcomes. The presence of these mutations was associated with shorter survival rates in patients with lung and other aggressive cancers.
A new study found that white blood cells that remember past inflammation events are quick to overreact, raising the risk of blood clots. Researchers discovered that these immune cells, called myeloid cells, have increased blood-clotting activity long after the initial inflammatory event.
Researchers found that immunosuppression in prostate cancer is associated with a specialised epithelial subtype. This interaction between the immune system and club-like epithelial cells can lead to treatment resistance in patients with advanced, treatment-resistant prostate cancer.
Researchers at WVU are working on a project to inhibit the myeloperoxidase enzyme, which feeds pancreatic cancer growth. By targeting this enzyme, they hope to boost the body's immune system to fight cancer, showing promise in mouse models and potential for future clinical trials.
Scientists identify PI3K gamma as a key player in recruiting damaging myeloid cells to infected tissues, and show that inhibiting this enzyme with eganelisib can prevent excessive inflammation. The study provides a new approach to preventing irreversible organ damage in infectious diseases like COVID-19.
In animal models, increasing mTOR activity just slightly accelerates aging and shortens lifetime by up to 20%. This research provides clues on why obesity-related diseases worsen with age. A new model allows researchers to study the relationship between nutrient increase and organ aging.
A recent study has identified Nup358 as a critical regulator of myeloid cell development, revealing its role in the differentiation process of early progenitors. The findings provide insights into how alterations in Nup358 contribute to blood malignancies and may lead to novel therapies targeting transport machinery like NPCs.
Researchers found that abnormally active B cell metabolism causes an inflammatory immune response in individuals with Multiple Sclerosis (MS), leading to nerve damage and symptoms. Emerging BTK inhibitors alter this abnormal B cell respiration, stopping the signaling that leads to MS flare-ups.
Researchers at USC Stem Cell lab discovered nearly 40 genes associated with immune cell production, including those related to diseases like myelodysplastic syndrome. The study found that gene activity was linked to specific levels of immune cell production, offering insights for improving bone marrow transplantation strategies.
A recent study published in Nature Communications reveals that disrupted NAD(H) homeostasis is a key factor in tuberculosis pathogenesis. The researchers found that the glycolytic pathway can be selectively inhibited using an LDH enzyme with mostly LDHA subunits, which preferentially converts pyruvate to lactate and NADH to NAD+.
A recent study found elevated TonEBP expression in patients with lupus nephritis, correlating with inflammatory cytokines and kidney damage. Suppressing TonEBP was shown to halt lupus progression and mitigate kidney damage in animal models.
Researchers tracked immune cell clusters in the aging mouse prostate using highly multiplexed immune profiling. Early adulthood sees myeloid cells, while between 6-12 months old, there's a profound shift to T and B lymphocyte-dominance. The study reveals new insight into prostatic inflammaging and the window for interventions.
Researchers at Mount Sinai have discovered a previously unknown way in which the brain and immune system interact in multiple sclerosis. They found that the inflammatory protein interleukin-3 (IL-3) coordinates this communication, inciting the recruitment of immune cells to the brain and exacerbating brain inflammation.
Cancer cells have been found to employ a strategy to evade the immune system's killer T cells by interacting with myeloid cells and suppressing type 1 interferon production. This natural pathway is crucial for recruiting killer T cells to combat cancer spread. Researchers hope to develop new therapeutic approaches, such as forcing tumo...
Reducing mRNA methylation promotes migration of macrophages into the brain and clearance of toxic protein amyloid-beta. This pathway provides a potential new target for treatment of Alzheimer's disease.
Researchers review myeloid-derived suppressor cells' phenotypes, mechanisms of immunosuppression, and roles in cancer treatment. Studies on non-malignant diseases, such as autoimmune disorders and obesity, are lacking, highlighting the need for further investigation.
Researchers identified toll-like receptor (TLR) signaling as a novel pathway regulating GLI3 expression, which plays a role in inflammatory cytokine production and cancer. They found that IRF3 directly binds to the GLI3 promoter region, increasing its expression upon TLR4 stimulation.
Researchers have discovered a protein produced by soft-tissue sarcoma tumors that changes the biology of surrounding immune cells, promoting tumor growth. The study could lead to improved treatments for this rare and aggressive cancer type.
Researchers at Karolinska Institutet have successfully repurposed a cancer drug to target neuroinflammatory diseases like multiple sclerosis. A novel drug carrier was developed to deliver the treatment specifically to microglia, reducing inflammation and disease progression.
Researchers have discovered a way to suppress a specific protein that promotes resistance to drugs commonly used to treat AML patients. This breakthrough has the potential to revolutionize treatment and prolong survival for those affected by the disease.
Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.
A Swiss-French team has identified a mechanism that could lead to the development of new therapies for acute myeloid leukaemia, a particularly dangerous form of cancer. The selective activation of AMPK triggers apoptosis in tumour cells by initiating the cell's stress response.
Researchers found that inhibiting gasdermin D, a protein involved in septic patients' organ lesions, can prevent multiple-organ damage and improve prognosis. Disulfiram, a drug originally indicated for alcohol dependence, was shown to inhibit gasdermin D and reduce tissue injury.
Researchers at Trinity College Dublin have identified a crucial protein, myeloid cell nuclear differentiation antigen (MNDA), that regulates type I interferon production in response to viral infections. This breakthrough discovery has significant implications for the development of new therapies to boost or suppress immune responses, p...
Research suggests that obesity triggers inflammation, leading to an increase in myeloid-derived suppressor cells, which break down bone tissue. This can result in gum disease and tooth loss. The study found a significant link between high-fat diets and increased osteoclasts and alveolar bone destruction.
Researchers from the University of Tsukuba found that blocking CD300a enhances efferocytosis and ameliorates neuronal deficits after ischemic stroke. This process involves the removal of damaged cells in the brain, reducing inflammation and neurological impairment.
Researchers discovered that patients with severe COVID-19 have significantly elevated levels of M-MDSCs in their blood compared to milder cases and healthy individuals. These findings suggest a potential connection between early immune responses and disease severity.
A Stanford study reveals that chronic inflammation driven by myeloid cells is the main driver of brain aging. The researchers found that blocking a specific hormone-receptor interaction in these cells can restore youthful metabolism and calm down inflammation, potentially reversing age-related cognitive decline.
Researchers have discovered a new class of immunotherapy that targets myeloid immune cells and slows tumor growth by inhibiting the c-Rel molecule. The treatment showed promising results in both human cells and mouse models, shrinking tumors by up to 80% and reducing immune suppressor cells.
A study published in Journal for ImmunoTherapy of Cancer found that introducing bone marrow cells with a specific gene deletion can induce an immune response against prostate and pancreatic cancer cells. The technique, known as adoptive cell therapy, uses patients' own marrow cells to target cancer.
Researchers discover a potential therapy that can disrupt the recruitment of myeloid cells by cancerous tumors, boosting the function of disease-fighting M1 type of myeloid cells. This approach shows great promise in reducing tumor growth and promoting a microenvironment where T cells can attack cancer.
Researchers are exploring the interaction between vascular smooth muscle cells (VSMC) and myeloid cells in blood circulation to identify novel biomarkers for unstable plaques. This project aims to develop therapeutic targets for treating blood vessel complications in hypertension, potentially preventing heart attacks and stroke.
A new study by IRB Barcelona researchers reveals that myeloid cells use p38 protein signalling to support inflammation-associated colon cancer. The study suggests IGF-1 as a potential therapeutic target in combination with prior detection of inflammatory infiltration in biopsies.
Research suggests that bone cells can release signals driving prostate cancer progression and growth, especially when cancer metastasizes to bone. A study found that inhibiting BMP signaling in myeloid cells could restrict cancer cell production and tumor growth.
Researchers have identified a crucial role for myeloid-derived suppressor cells (MDSCs) in regulating inflammation in newborns. These immature immune cells help control the inflammatory response during the first weeks of life, and their accumulation is linked to milk feeding.
Researchers have identified a distinctive epigenetic event in immune cells that differentiate in the tumoral microenvironment, making them tolerant to cancer cells. The study found that DNA methyltransferase 3A is responsible for the acquisition of suppressive properties in these cells.
Researchers at Penn State College of Medicine discovered that certain viruses evade the innate immune system by spreading to blood and being fought off in organs like the liver and spleen. This finding could lead to better treatments for viral infections like Zika, dengue, and measles.
Researchers identified a network of genes expressed in myeloid cells that contribute to Alzheimer's disease pathogenesis. A protein called PU.1 regulates this gene network, which may hold promise for therapeutic targets.
Research highlights the role of myeloid-derived suppressor cells in regulating immune responses to viral infections. These cells have been shown to directly alter the viral infectious process, posing challenges for developing antiviral therapies.
A study by Helmholtz Zentrum München found that myeloid-derived suppressor cells (MDSC) are increased in the blood of patients with idiopathic pulmonary fibrosis (IPF), correlating with lung function decline. MDSC may serve as a biomarker for IPF diagnosis and disease progression.
Researchers analyzed myeloid lineage immune cells in glioblastoma patients, revealing non-polarized cell state and potential therapeutic strategy. The study suggests stimulating these cells to adopt an anti-tumor identity may be effective.
Researchers at The Wistar Institute found that hypoxia in tumors lowers STAT3 activity, allowing myeloid-derived suppressor cells to differentiate into tumor-associated macrophages. A combination of an experimental STAT3 inhibitor and sialidase showed substantial antitumor activity
Researchers at MD Anderson Cancer Center identified myeloid-derived suppressor cells (MDSCs) as a key player in advanced prostate cancer progression. Depletion of MDSCs and blocking specific signaling pathways showed promise in suppressing tumor growth, paving the way for potential therapeutic opportunities.
A new study has discovered how the enzyme heme oxygenase-1 (HO-1) regulates immune cells in response to kidney injury. The research found that HO-1 directs a specific subset of myeloid cells to and from the kidney, which helps protect against poor recovery after acute kidney injury.
Scientists identify tumor necrosis factor alpha (TNFα) as a key player in the emergence of hematopoietic stem cells, a breakthrough that could aid in developing induced pluripotent stem cell replacements for blood disorders. The discovery sheds light on the complexities of HSC genesis and paves the way for further research.
A team of researchers at the University of Illinois Chicago has identified a single receptor, TLR5, that triggers inflammation and bone degradation in rheumatoid arthritis. Blocking this receptor may provide a new therapeutic target to interrupt the disease's vicious cycle.
U of M researchers identified infection-fighting and inflammation-suppressing functions for the PTPN22 gene, which could impact treatment strategies for autoimmune diseases. The study found that a variant of PTPN22 impacts immune system function in health and disease.
Researchers have successfully rejuvenated the blood of mice by reprogramming their stem cells, reversing epigenetic changes that occur with age. This breakthrough could potentially lead to new treatments for diseases such as leukemia, where cancer often originates in older, damaged bone marrow.
Researchers at Moffitt Cancer Center have found that blocking myeloid-derived suppressor cells and regulatory T-cell reconstitution improves adoptive T-cell therapy for melanoma. This blockade is achieved after total body irradiation eliminates these cells, leading to delayed tumor growth and enhanced survival in mice.
Researchers discovered that the interaction between CD4 T cells and myeloid-derived suppressor cells (MDSC) can inhibit T-cell function, while CD8 T cells are not affected. The study suggests a potential mechanism for controlling dysregulated immune responses in cancer.